Frontiers in Pharmacology (Jul 2020)

ADAM17-Mediated Shedding of Inflammatory Cytokines in Hypertension

  • Thyago M. de Queiroz,
  • Navya Lakkappa,
  • Navya Lakkappa,
  • Eric Lazartigues,
  • Eric Lazartigues

DOI
https://doi.org/10.3389/fphar.2020.01154
Journal volume & issue
Vol. 11

Abstract

Read online

The increase of Angiontesin-II (Ang-II), one of the key peptides of the renin-angiotensin system (RAS), and its binding to the Ang-II type 1 receptor (AT1R) during hypertension is a crucial mechanism leading to AD\AM17 activation. Among the reported membrane anchored proteins cleaved by ADAM17, immunological cytokines (TNF-α, IFN-γ, TGF-β, IL-4, IL-10, IL-13, IL-6, FKN) are the major class of substrates, modulation of which triggers inflammation. The rise in ADAM17 levels has both central and peripheral implications in inflammation-mediated hypertension. This narrative review provides an overview of the role of ADAM17, with a special focus on its cellular regulation on neuronal and peripheral inflammation-mediated hypertension. Finally, it highlights the importance of ADAM17 with regards to the biology of inflammatory cytokines and their roles in hypertension.

Keywords